Invitrogen Advances Next Generation Sequencing Workflows

CARLSBAD, Calif.–Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the launch of the SequalPrep™ System; a complete sample enrichment and normalization solution for next generation sequencing technologies that consists of the SequalPrep™ Long PCR Kit and the SequalPrep™ Normalization Plate (96) Kit. One of the most medically significant applications of next generation sequencing technologies is the sequencing of specific DNA regions to identify rare genetic mutations that might contribute to disease development. To accomplish this, scientists select DNA sections associated with a disease state and amplify them using PCR. The resulting sections are put into next generation sequencing processing where they are assembled to determine the exact nucleotide sequence for further analysis. “Proper sample preparation is a crucial part of the sequencing process and this kit is an important step forward in reducing time, labor, expense and possible inaccuracies,” said Kip Miller, senior vice president, BioDiscovery. “Invitrogen is a leader in genomic analysis and the launch of this system once again demonstrates the importance of our role in advancing the next generation of genomic sequencing.” The SequalPrep™ Long PCR Kit allows researchers to reduce the number of enrichment reactions required by providing long range PCR with high amplification success of up to 20 kilobases and little or no optimization. Other long PCR kits often require a substantial investment of time and effort to find the precise experimental conditions that will yield enough PCR product for subsequent sequencing. In addition, in order to achieve higher depth of coverage across the entire DNA region, researchers must ensure the starting material for each DNA section is relatively equivalent or normalized. The SequalPrep™ Normalization Plate (96) Kit reduces labor and errors by providing one-step PCR product purification and normalization. For more information, visit About Invitrogen Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen’s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology — placing Invitrogen’s products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit Safe Harbor Statement Certain statements contained in this press release are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen’s intent that such statements be protected by the safe harbor created thereby. Potential risks and uncertainties include, but are not limited to; a) the SequalPrep™ System may or may not reduce time, labor, expense and inaccuracies in DNA sample preparation; the risks that the market will not accept the companies’ products and services, or that the companies will be unsuccessful in their efforts to develop new products and services, as well as other risks and uncertainties detailed from time to time in Invitrogen’s Securities and Exchange Commission filings.

< | >